CRIS Current Research Information System

SARTOR, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.577
NA - Nord America 5.564
EU - Europa 3.919
AF - Africa 382
SA - Sud America 335
Continente sconosciuto - Info sul continente non disponibili 334
OC - Oceania 10
Totale 17.121
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.405
VN - Vietnam 2.139
SG - Singapore 1.587
CN - Cina 1.487
IT - Italia 1.001
GB - Regno Unito 755
DE - Germania 462
SE - Svezia 462
HK - Hong Kong 390
FR - Francia 242
BR - Brasile 226
IN - India 220
KR - Corea 208
NL - Olanda 193
RU - Federazione Russa 154
FI - Finlandia 141
IE - Irlanda 133
BD - Bangladesh 114
JP - Giappone 104
ZA - Sudafrica 91
CA - Canada 85
TG - Togo 82
CI - Costa d'Avorio 70
SC - Seychelles 57
EE - Estonia 54
NG - Nigeria 53
JO - Giordania 45
BG - Bulgaria 44
CH - Svizzera 43
AR - Argentina 41
UA - Ucraina 41
PH - Filippine 38
ID - Indonesia 36
TH - Thailandia 33
IQ - Iraq 31
MX - Messico 31
ES - Italia 30
PL - Polonia 30
BE - Belgio 29
AT - Austria 27
TR - Turchia 25
TW - Taiwan 22
EC - Ecuador 17
IR - Iran 17
GR - Grecia 15
PK - Pakistan 14
UZ - Uzbekistan 13
VE - Venezuela 11
PY - Paraguay 10
CL - Cile 9
LT - Lituania 9
AU - Australia 8
JM - Giamaica 8
PE - Perù 8
AE - Emirati Arabi Uniti 7
CR - Costa Rica 7
PT - Portogallo 7
TN - Tunisia 7
CO - Colombia 6
EU - Europa 6
MA - Marocco 6
MY - Malesia 6
RO - Romania 6
RS - Serbia 6
CZ - Repubblica Ceca 5
HN - Honduras 5
HR - Croazia 5
LB - Libano 5
MK - Macedonia 5
SA - Arabia Saudita 5
TT - Trinidad e Tobago 5
AL - Albania 4
EG - Egitto 4
IL - Israele 4
KZ - Kazakistan 4
NP - Nepal 4
SV - El Salvador 4
UY - Uruguay 4
BY - Bielorussia 3
HU - Ungheria 3
NI - Nicaragua 3
OM - Oman 3
QA - Qatar 3
DZ - Algeria 2
GD - Grenada 2
GT - Guatemala 2
GY - Guiana 2
KE - Kenya 2
KG - Kirghizistan 2
KH - Cambogia 2
LI - Liechtenstein 2
MN - Mongolia 2
NZ - Nuova Zelanda 2
SO - Somalia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BS - Bahamas 1
Totale 16.770
Salva come PNG Salva come JPEG
Città #
Singapore 1.124
Ashburn 672
Southend 663
Ho Chi Minh City 460
San Jose 431
Chandler 429
Dong Ket 418
Hanoi 393
Hong Kong 359
Hefei 325
Fairfield 271
Beijing 228
Bologna 186
Santa Clara 183
Ann Arbor 180
Seoul 180
Dallas 163
Houston 162
Wilmington 148
Woodbridge 145
Boardman 138
Princeton 134
Dublin 133
Seattle 123
Council Bluffs 113
New York 111
Helsinki 106
Cambridge 98
Milan 94
Los Angeles 88
Tokyo 86
Lauterbourg 84
Lomé 82
Abidjan 70
São Paulo 59
Haiphong 57
Frankfurt am Main 56
Nanjing 55
Westminster 55
Padova 52
Rome 50
Munich 49
Abeokuta 47
Da Nang 47
Buffalo 45
Medford 45
Sofia 44
Amman 41
Berlin 38
Bremen 36
Redondo Beach 35
Florence 31
Johannesburg 31
Turin 31
Bengaluru 30
Shanghai 30
Brussels 29
Redmond 29
Saint Petersburg 27
San Diego 27
Bern 26
Redwood City 26
Shenyang 26
London 25
Biên Hòa 24
Guangzhou 24
Jinan 24
Tianjin 24
Toronto 24
Changsha 23
Chicago 23
Zhengzhou 22
Hebei 20
Orem 20
Thái Nguyên 20
Jakarta 19
Nanchang 19
Baghdad 18
Falkenstein 18
Hải Dương 18
Phoenix 18
Turku 18
Ha Long 17
Jiaxing 17
Nuremberg 17
Vienna 17
Atlanta 16
Can Tho 15
Lappeenranta 15
Montreal 15
Stockholm 15
Warsaw 15
Amsterdam 14
Wuhan 13
Bangkok 12
Fuzhou 12
Mexico City 12
Mountain View 12
Brooklyn 11
Chengdu 11
Totale 10.391
Salva come PNG Salva come JPEG
Nome #
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 667
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 326
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 295
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 266
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 257
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 256
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 250
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 250
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 247
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 243
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 242
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 241
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 240
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 234
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 231
A case report of acute myeloid leukemia and neurofibromatosis 1 223
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 215
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 214
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 212
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 211
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 210
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 208
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure 204
INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia 201
Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia 199
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 198
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission 197
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 195
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 194
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 194
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 194
Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: A pilot study 194
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 193
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 191
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 191
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 189
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 186
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 185
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 182
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 180
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 180
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 176
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 176
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 176
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 175
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 174
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 172
SNP array reveals a new deletion of JAK2 in AML patients 171
Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Results from a survey among allergists and clinical immunologists of the North-west and Center Italy Inter-Regional Sections of SIAAIC and otorhinolaryngologists of National IAR 170
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 170
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 169
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 166
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 164
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease 163
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 161
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 160
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 160
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 160
HIGH RATE OF COMPLETE HEMATOLOGICAL RESPONSE IN ELDERLY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY INNOVATIVE SEQUENTIAL USE OF NILOTINIB AND IMATINIB: A GIMEMA CLINICAL TRIAL LAL 1408 159
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 159
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 158
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 154
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 153
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 153
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 152
Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia 152
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 147
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 144
Nelarabine front-line therapy for adult T-Lymphoblastic leukaemia/Lymphoma (T-LBL/ALL): preliminary results of a single centre experience 144
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 143
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study 142
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 137
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 136
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis 133
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 132
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 131
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 131
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 130
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 129
Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience 129
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 128
MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis 125
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 125
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax / hypomethylating agents 123
Nelarabine front-line therapy for adult T-lymphoblastic leukemia/lymphoma (T-LBL/ALL): preliminary results of a single center experience. 122
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement 120
COMPARISON BETWEEN NGS IGH/TCR AND RT-PCR BCR::ABL1 MINIMAL RESIDUAL DISEASE IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY ANALYSIS 119
Single-Cell Metabolic Profiling Integrated with Extracellular Vesicle Analysis Reveals Novel Metabolic Vulnerabilities and Prognostic Biomarkers in Acute Myeloid Leukemia 98
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin 88
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 88
Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment 83
Posterior reversible encephalopathy syndrome in a B-cell acute lymphoblastic leukemia young adult patient treated with a pediatric-like chemotherapeutic schedule 73
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax 65
Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment 64
Acute myeloid leukemia mutations: Therapeutic implications 56
null 52
null 50
Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 49
Posterior Reversible Encephalopathy Syndrome in a B-Cell Acute Lymphoblastic Leukemia Young Adult Patient Treated with a Pediatric-like Chemotherapeutic Schedule 49
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study 26
Totale 17.099
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.269
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.269
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.366 0 35 69 141 137 65 33 117 69 125 322 253
2022/20231.841 184 254 74 235 197 154 49 115 310 45 137 87
2023/2024602 16 73 38 62 38 118 43 62 31 39 53 29
2024/20252.662 113 361 212 207 245 122 268 113 48 264 209 500
2025/20267.019 620 1.159 498 483 614 305 586 248 1.440 510 273 283
2026/2027398 184 214 0 0 0 0 0 0 0 0 0 0
Totale 17.121